Vagus Nerve Stimulation Improves Quality of Life in Hard-to-Treat Depression
A year-long sham-controlled trial finds active VNS meaningfully improves daily function and quality of life in patients who failed 4+ antidepressants.
Summary
For people with severe, treatment-resistant depression who have failed multiple medications, vagus nerve stimulation (VNS) — a device implanted near the collarbone that sends electrical pulses to the brain via the vagus nerve — showed meaningful improvements in quality of life and daily functioning over 12 months. In a rigorous double-blind trial of 493 adults, those receiving active VNS spent significantly more time experiencing clinically meaningful benefit compared to those receiving sham stimulation. Effects were seen across multiple quality-of-life measures, including the ability to perform regular activities. While not all outcome measures reached statistical significance, the overall pattern favors VNS as a therapy that goes beyond just reducing depressive symptoms to genuinely improving how patients live day to day.
Detailed Summary
Treatment-resistant depression (TRD) is one of the most debilitating conditions in psychiatry, affecting millions of people who fail to respond to multiple antidepressant therapies. Beyond symptom burden, TRD severely impairs quality of life, work productivity, and social functioning. Understanding whether interventions can restore these dimensions of wellbeing — not just reduce symptom scores — is critical for both patients and clinicians.
This multicenter, double-blind, sham-controlled trial enrolled 493 adults with markedly TRD, defined as failing at least four adequate antidepressant treatment trials during the current episode. Participants were randomized to active VNS (n=249) or sham VNS (n=244), both added to treatment as usual, and followed for 12 months with quarterly assessments using validated quality-of-life and functional outcome tools.
Active VNS outperformed sham on several key measures. Statistically significant advantages were found for time spent in clinically meaningful benefit on the Q-LES-Q (P=0.029), Mini-Q-LES-Q (P=0.011), and the Work Productivity and Activity Impairment item 6 (P=0.039). Continuous score analyses also favored active VNS on the Mini-Q-LES-Q and WPAI item 6 (both P=0.050). Two other measures — the WHODAS 2.0 and EQ-5D visual analog scale — did not show significant between-group differences.
These findings suggest VNS delivers a broader therapeutic benefit than symptom reduction alone, meaningfully improving how patients with severe TRD function and experience daily life. This is particularly important given that functional restoration is often the primary goal for patients and caregivers.
Several caveats apply. This summary is based on the abstract only, limiting full methodological appraisal. Multiple authors have financial ties to LivaNova, the VNS device manufacturer, introducing potential bias. Not all outcome measures reached significance, and the patient population — those failing four or more treatments — may limit generalizability to broader depression populations.
Key Findings
- Active VNS patients spent significantly more time with clinically meaningful quality-of-life improvement vs. sham over 12 months.
- VNS improved ability to perform regular daily activities (WPAI item 6, P=0.039) beyond symptom reduction.
- Benefits were consistent across multiple validated QoL tools, though two measures (WHODAS 2.0, EQ-5D) did not reach significance.
- Trial enrolled patients who had failed 4+ antidepressant treatments — among the most difficult-to-treat depression cases.
- VNS effects extended beyond symptom scores to functional and psychosocial domains, a clinically meaningful distinction.
Methodology
Multicenter, double-blind, sham-controlled RCT with 493 adults randomized to active or sham VNS plus treatment as usual over 12 months. Outcomes assessed quarterly using five validated instruments covering quality of life, work productivity, and psychosocial function. Both continuous change-from-baseline and categorical meaningful-response analyses were performed.
Study Limitations
This summary is based on the abstract only, as the full text is not open access, limiting assessment of methodology, adverse events, and dropout rates. Multiple authors and several co-investigators have financial relationships with LivaNova, the device manufacturer, which may introduce bias. Not all outcome measures reached statistical significance, and findings may not generalize beyond patients with four or more failed antidepressant trials.
Enjoyed this summary?
Get the latest longevity research delivered to your inbox every week.